Oncotarget

Clinical Research Papers:

Screening for distress in patients with intracranial tumors during the first 6 months after diagnosis using self-reporting instruments and an expert rating scale (the basic documentation for psychooncology short form – PO-Bado SF)

Mirjam Renovanz _, Helena Tsakmaklis, Sari Soebianto, Isabell Neppel, Minou Nadji-Ohl, Manfred Beutel, Andreas Werner, Florian Ringel and Anne-Katrin Hickmann

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:31133-31145. https://doi.org/10.18632/oncotarget.25763

Metrics: PDF 1286 views  |   HTML 1902 views  |   ?  


Abstract

Mirjam Renovanz1, Helena Tsakmaklis1, Sari Soebianto1, Isabell Neppel1, Minou Nadji-Ohl2, Manfred Beutel4, Andreas Werner4, Florian Ringel1 and Anne-Katrin Hickmann2,3

1Department of Neurosurgery, University Medical Center, Johannes-Gutenberg-University of Mainz, Mainz, Germany

2Department of Neurosurgery, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany

3Department of Spine Surgery and Neurosurgery, Schulthess Klinik, Zürich, Switzerland

4Department of Psychosomatic Medicine and Psychotherapy, University Medical Center, Johannes-Gutenberg-University of Mainz, Mainz, Germany

Correspondence to:

Mirjam Renovanz, email: [email protected]

Keywords: brain tumor patients; psychosocial screening; Po-BADO; external assessment; neuro-oncology

Received: February 21, 2018     Accepted: June 22, 2018     Published: July 24, 2018

ABSTRACT

Objective: Psychosocial screening in brain tumor patients is of high importance. We applied The Basic Documentation for Psycho-Oncology Short Form (PO-Bado SF) in primary brain tumor patients and patients with metastasis. The aim was to evaluating consistency between physicians' perception and the results of the patients' self-assessment.

Materials and Methods: 140 patients with first diagnosis of a brain tumor were screened during their hospital stay (t1) using Distress Thermometer (DT) and Hornheide Screening Instrument (HSI), health-related quality of life was assessed by EORTC QLQ-C30 + BN20. After 3 (t2) and 6 months (t3), patients were re-evaluated. Attending neuro-oncologists completed the PO-Bado SF at all three time points (cut-off for being in need for support >8).

Results: At t1, the mean of the PO-Bado SF total score was 7.71 (SD = 4.08), at t2 8.22 (SD = 5.40) and at t3 7.62 (SD = 5.72).

The proportion of patients reaching a total score >8 was at t1: 43%, at t2: 41% and at t3: 47% (t1–3). Discrimination of PO-Bado SF total score, between patients in (DT ≥6) and those not in distress was more sensitive (cut-off 8.5, AUC 0.772, sens. 71.3%, spec. 67.6%) than discrimination compared to the HIS (cut-off 9.5, AUC 0.779, sens. 65.1%, spec. 77.7%). Higher PO-Bado-SF total score correlated with higher DT scores (r = 0.6, p < 0.0001) and lower EORTC GHS scores (r = −0.55, p < 0.0001).

Conclusion: Physicians' perception according to PO-Bado SF provides a different measure for psychosocial burden in patients with brain tumors, however does not completely reflect patients' wishes.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25763